EPH6

Cost and Use of Medical Devices in Incident Early-Onset Myasthenia Gravis Patients in France

Cécile Blein,*[1] Shahram Attarian,[2] Jean-Philippe Camdessanché,[3] Guilhem Solé,[4] Mariana Ciumas,[1] Andoni Echaniz-Laguna[5]

*Presenting author

[1]argenx BV, Ghent, Belgium; [2]Reference Center for Neuromuscular Disease and ALS, Timone University Hospital, Aix-Marseille University, CHU Timone, Filnemus, Euro-NMD, Marseille, France; [3]Department of Neurology, Neuromuscular Disease Reference Center, Hôpital Nord, University Hospital of Saint-Étienne, Euro-NMD, Saint-Étienne, France; [4]Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department, Pellegrin Hospital, Bordeaux University Hospitals, Bordeaux, France; [5]Department of Neurology, APHP, CHU de Bicêtre, INSERM U1195, Paris-Saclay University, Le Kremlin-Bicêtre, France

Background

- Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction and is caused by auto-antibodies directed at the muscle acetylcholine receptors.[1,2]
- MG is associated with a considerable burden of disease; patients are significantly impacted in both the short and long term, and many experience inadequate disease control, poor quality of life, and fixed muscle weakness.[3-6]
- In a previous longitudinal claim-based study in France, we reported that 34.6% of the 6,354 patients with incident MG were admitted to intensive care at least once, and 44.3% were treated with intravenous immunoglobulin during follow-up.[7]
- Understanding the progression of disability in MG is important in informing treatment strategies and improving patient care, but such data are scarce, particularly in patients with early-onset MG (onset at age <50 years).[8-11]

Objectives

- To (i) assess the use of medical devices as a proxy for extent of disability, and (ii) evaluate the costs of medical device use over time in patients with incident early-onset MG compared with the overall cohort of patients with incident MG.

Methods

Study design and data source[7]

- This was a retrospective, longitudinal cohort study using the French national health insurance claims database (SNDS) from January 2013 to December 2020 (Figure 1).
- The index date was the date of the first healthcare reimbursement claim relating to MG documented during the study period.
- Patients were followed from the index date to the end of the study period (31 December 2020) or until death.
- A 3-year historical period dating from 1 January 2010 was also searched for previous MG-related claims.



Reproduced from Attarian S, et al., 2024[7] with permission from the authors. © 2024 The Authors.
MG, myasthenia gravis.

FIGURE 1. **Study design[7]**

Patient population

- Patients aged ≥18 years were included in the full study population according to eligibility criteria that have been previously described.[7]
- Claims for delivery of an acetylcholinesterase inhibitor prescribed by a gastroenterologist were excluded.[7]
- Patients with <12 months of follow-up were excluded.
- Incident patients were defined as all patients with a first MG-related claim during the inclusion period and no history of any MG-related claim during the historical period between 1 January 2010 and the index date.[7]
- Early-onset MG was defined as onset of MG before the age of 50 years.[8-11]

Study outcomes

- Outcomes were assessed in the incident early-onset MG cohort and the overall incident MG cohort.
- Medical device use and costs were assessed during the follow-up period.
- Use of medical devices included products and equipment reimbursed by French national insurance, such as dressings, wheelchairs, orthoses, and external prostheses.
- Costs were reported in Euros (€) at 2022 prices.

Statistical analysis

- Descriptive statistics were used to summarize the baseline characteristics and outcomes of the study populations.

Results

Patient selection

- Among the 14,459 patients with MG included in the full study population, 6,354 patients had incident MG and 1,802 patients had incident early-onset MG (Figure 2).



Ab, antibody; **AChE-I**, acetylcholinesterase inhibitor; **EDX**, electrodiagnostic evaluation; **ICD-10**, International Classification of Diseases 10th Revision; **LTD**, long-term disease; **MG**, myasthenia gravis; **SNDS**, *Système National des Données de Santé* (French national health insurance claims database).

FIGURE 2. **Patient flow**

Baseline demographic and clinical characteristics

- Patients with incident early-onset MG were younger than those in the overall cohort with incident MG, and the proportion of female patients was higher (Table 1).
- Patients with incident early-onset MG had lower mean Charlson Comorbidity Index scores and had fewer comorbidities compared with the overall cohort with incident MG, including infections, asthma/chronic obstructive pulmonary disease, and cancer (Table 2).

TABLE 1. **Baseline demographic characteristics**

Characteristic	Incident early-onset MG (N=1,802)	Overall incident MG (N=6,354)
Age, years		
Mean (SD)	35.65 (8.94)	59.94 (18.34)
Median (IQR)	36 (28–44)	63 (47–74)
Distribution by age, n (%)		
18–40 years	1,149 (63.8)	1,149 (18.1)
41–65 years	653 (36.2)	2,310 (36.4)
>65 years	0 (0)	2,895 (45.6)
Sex, n (%)		
Male	611 (33.9)	4,424 (69.6)
Female	1,191 (66.1)	1,930 (30.4)
Follow-up		
Mean (SD), years	4.56 (2.19)	4.32 (2.23)

IQR, interquartile range; **MG**, myasthenia gravis; **SD**, standard deviation.

TABLE 2. **Baseline clinical characteristics**

Characteristic	Incident early-onset MG (N=1,802)	Overall incident MG (N=6,354)
Charlson Comorbidity Index[a]		
Mean (SD)	0.30 (0.55)	2.73 (1.95)
0, n (%)	1,326 (73.6)	3,612 (56.8)
1–2, n (%)	466 (25.9)	2,461 (38.7)
3–4, n (%)	10 (0.6)	255 (4.0)
≥5, n (%)	0 (0)	26 (0.4)
Comorbidities, n (%)		
Infection	159 (8.8)	857 (13.5)
Depression	147 (8.2)	663 (10.4)
Anxiety	105 (5.8)	681 (10.7)
Asthma/COPD	95 (5.3)	601 (9.5)
Hypertension	90 (5.0)	1,505 (23.7)
Cancer	75 (4.2)	688 (10.8)
Cardiovascular disease	35 (1.9)	811 (12.8)

[a]Charlson Comorbidity Index without age adjustment.
COPD, chronic obstructive pulmonary disease; **MG**, myasthenia gravis; **SD**, standard deviation.

Use of medical devices

- The use of medical devices was high among patients with incident early-onset MG; 91.5% of patients received a prescription for a medical device during follow-up (data not shown), with 69.0% of patients using medical devices during Year 1 (Figure 3).
- The mean annual cumulative number of medical devices per patient increased from 6.3 devices in Year 1 to 8.4 devices in Year 5 in the incident early-onset cohort (33% increase), compared with 8.7 and 9.5 devices, respectively, in the overall incident cohort (9% increase; Figure 4).



The number of patients in the incident early-onset cohort were: Year 1, n=1,802; Year 2, n=1,686; Year 3, n=1,516; Year 4, n=1,303; and Year 5, n=1,086. The number of patients in the overall incident cohort were: Year 1, n=6,354; Year 2, n=5,905; Year 3, n=5,184; Year 4, n=4,358; and Year 5, n=3,531. The numbers decline by year primarily because MG diagnosis could occur at any time from 2013 to 2019, and therefore patients had a variable length of follow-up during the study period.
MG, myasthenia gravis.

FIGURE 3. **Proportion of patients using medical devices in incident early-onset MG vs overall incident MG**



MG, myasthenia gravis.

FIGURE 4. **Evolution of the use of medical devices in incident early-onset MG vs overall incident MG**

Medical device costs

- Mean medical device costs per patient in the incident early-onset cohort increased by 93% from Year 1 (€388) to Year 5 (€750; Figure 5).
- By contrast, mean medical device costs per patient in the overall incident cohort increased by 25% from Year 1 (€492) to Year 5 (€615).



MG, myasthenia gravis.

FIGURE 5. **Evolution of the mean cost of medical devices in incident early-onset MG vs overall incident MG**

Conclusions

- **Despite being younger and having fewer comorbidities than the overall cohort with incident MG, patients with incident early-onset MG exhibit high medical device usage with related rapidly rising costs, particularly in the first year after diagnosis.**
- **Medical device costs increased over time, highlighting the need for continued support and optimized care strategies for this subgroup.**
- **These findings underscore the importance of early interventions to improve long-term outcomes and reduce disease burden in early-onset MG.**

Limitations

- Structured fields do not provide results specifying whether the electro-neuro-myogram result was normal or abnormal.
- The SNDS claims database does not provide medical information.

Funding
This study was funded by Laboratoire argenx, Issy-les-Moulineaux, France.

Disclosures
CB and MC are employees of argenx. SA, J-PC, and GS have received honoraria from argenx for board participation or as a speaker at symposia. GS has received support from argenx to participate in medical meetings. GS has also received funding from argenx for the scientific policy of the French Society of Myology, paid to the French Society of Myology. AE-L has received consulting and expert fees, lecture honoraria, support for participation in medical meetings, and honoraria for board participation from argenx.

Acknowledgments
Medical writing support was provided by Mai Ping Tan, PhD, and Lisa Baker, PhD, of HEORpubs.

References
1. Gilhus NE, et al. *Nat Rev Dis Primers*. 2019;5(1):30. doi:10.1038/s41572-019-0079-y.
2. Vincent A, et al. *Lancet*. 2001;357(9274):2122–8. doi:10.1016/S0140-6736(00)05186-2.
3. Grob D, et al. *Muscle Nerve*. 2008;37(2):141–9. doi:10.1002/mus.20950.
4. Bozovic I, et al. *J Neurol*. 2022;269(4):2039–45. doi:10.1007/s00415-021-10759-4.
5. Law N, et al. *Neurol Ther*. 2021;10(2):1103–25. doi:10.1007/s40120-021-00285-w.
6. Cejvanovic S, Vissing J. *Acta Neurol Scand*. 2014;129(6):367–73. doi:10.1111/ane.12193.
7. Attarian S, et al. *Eur J Neurol*. 2025;32(1):e16518. doi:10.1111/ene.16518.
8. Gilhus NE, et al. *Autoimmune Dis*. 2011;2011:847393. doi:10.4061/2011/847393.
9. Saccà F, et al. *Eur J Neurol*. 2024;31(6):e16180. oi:10.1111/ene.16180.
10. Fan L, et al. *Neurol Res*. 2019;41(1):45–51. doi:10.1080/01616412.2018.1525121.
11. Wang W, et al. *Zhonghua Nei Ke Za Zhi* [Chinese Journal of Internal Medicine]. 2011;50(6):496–8. doi:10.3760/cma.j.issn.0578-1426.2011.06.013

Presented at ISPOR 2025, May 13–16, 2025, Montreal, Quebec, Canada